Integrative Biomarker Panel for Improved Lung Cancer Diagnosis Using Plasma microRNAs and Sputum Bacterial DNA

• Published in: Current oncology (Toronto) Vol. 31; no. 10; pp. 5949 - 5959
• Main Authors: Dhilipkannah, Pushpa, Sachdeva, Ashutosh, Holden, Van K, Jiang, Feng
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 02-10-2024; MDPI
• Subjects: Aged; Analysis; Bacterial genetics; biomarkers; Biomarkers, Tumor - blood; Cancer; Development and progression; Diagnosis; DNA; DNA, Bacterial - blood; DNA, Bacterial - genetics; early stage; Female; Genetic aspects; Humans; Lung cancer; Lung Neoplasms - blood; Lung Neoplasms - diagnosis; Lung Neoplasms - genetics; Male; MicroRNA; MicroRNAs - blood; Middle Aged; Oncology, Experimental; plasma; Smokers; Sputum - microbiology; lung cancer; diagnosis; plasma; biomarkers; early stage
• ISSN: 1718-7729; 1198-0052; 1718-7729
• DOI: 10.3390/curroncol31100444

This study aimed to evaluate if integrating diverse molecular biomarkers in plasma and sputum could improve the diagnosis of lung cancer. The study analyzed miRNAs in plasma and bacterial DNA in sputum from 58 lung cancer patients and 62 cancer-free smokers using droplet digital PCR. The individual plasma miRNA and sputum bacterial biomarkers had sensitivities of 62-71% and specificities of 61-79% for diagnosing lung cancer. A panel of plasma miRNA or sputum bacterial biomarkers produced sensitivities of 79-85% and specificities of 74-82%. An integromic signature consisting of two miRNAs in plasma and three bacterial biomarkers in sputum had a higher sensitivity (87%) and specificity (89%) compared to individual biomarkers. The signature's diagnostic value was confirmed in a validation cohort of 56 lung cancer patients and 59 controls, independent of tumor stage, histological type, and demographic factors. Integrating diverse molecular biomarkers in plasma and sputum could improve the diagnosis of lung cancer.